These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9093709)

  • 1. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis.
    Norum J; Vonen B; Olsen JA; Revhaug A
    Ann Oncol; 1997 Jan; 8(1):65-70. PubMed ID: 9093709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
    Smith RD; Hall J; Gurney H; Harnett PR
    Med J Aust; 1993 Mar; 158(5):319-22. PubMed ID: 8474372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic overview of chemotherapy effects in colorectal cancer.
    Ragnhammar P; Hafström L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
    de Souza P
    Med J Aust; 1993 Jun; 158(12):866. PubMed ID: 8326905
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
    Monz BU; König HH; Leidl R; Staib L; Link KH
    Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer.
    Messori A; Bonistalli L; Costantini M; Trallori G; Tendi E
    J Clin Gastroenterol; 1996 Dec; 23(4):269-74. PubMed ID: 8957728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
    Bleeker WA; Mulder NH; Hermans J; Otter R; Plukker JT
    Ann Oncol; 2000 May; 11(5):547-52. PubMed ID: 10907947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
    Wolmark N; Rockette H; Mamounas E; Jones J; Wieand S; Wickerham DL; Bear HD; Atkins JN; Dimitrov NV; Glass AG; Fisher ER; Fisher B
    J Clin Oncol; 1999 Nov; 17(11):3553-9. PubMed ID: 10550154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer.
    Chrisp P; McTavish D
    Drugs Aging; 1991; 1(4):317-37. PubMed ID: 1794023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.
    Tsavaris N; Gennatas K; Kosmas C; Skopelitis HM; Gouveris P; Dimitrakopoulos A; Zacharakis M; Kouraklis G; Vasiliou J; Felekouras E; Voros D; Zografos G; Balafouta M; Paraskevaidis M; Safioleas M; Fotiadis K; Papastratis G; Karatzas G; Papalambros E
    Oncol Rep; 2004 Oct; 12(4):927-32. PubMed ID: 15375524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
    Sculpher M; Palmer MK; Heyes A
    Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in Dukes' B and C colorectal cancer has only a minor influence on psychological distress.
    Norum J
    Support Care Cancer; 1997 Jul; 5(4):318-21. PubMed ID: 9257429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.
    Cashin PH; Mahteme H; Syk I; Frödin JE; Glimelius B; Graf W
    Eur J Surg Oncol; 2018 Jul; 44(7):983-990. PubMed ID: 29530346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04).
    Mamounas E; Wieand S; Wolmark N; Bear HD; Atkins JN; Song K; Jones J; Rockette H
    J Clin Oncol; 1999 May; 17(5):1349-55. PubMed ID: 10334518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
    Moertel CG; Fleming TR; Macdonald JS; Haller DG; Laurie JA; Tangen CM; Ungerleider JS; Emerson WA; Tormey DC; Glick JH
    J Clin Oncol; 1995 Dec; 13(12):2936-43. PubMed ID: 8523058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon-alpha in adjuvant treatment of colorectal carcinoma].
    Staib L; Link KH; Henne-Bruns D
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():142-5. PubMed ID: 12704877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.